Research and development method of products for screening high-incidence single-gene recessive genetic disease carriers in infertility period

Through specific primer design and high-throughput sequencing technology, a data analysis platform is built to identify potential carriers of single-gene recessive genetic diseases, solving the problems of inefficiency and error identification of traditional screening methods, and achieving more efficient and accurate genetics The disease screening has improved the level of reproductive health and public health awareness.

CN118932048APending Publication Date: 2024-11-12张莉 +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411336511.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The traditional screening method for carriers with high incidence of single-gene recessive genetic diseases during peri-pregnancy is inefficient and has problems with misidentification.

Method used

A combination of specific primer design, PCR amplification and high-throughput sequencing technology is used to build a data analysis platform to identify potential carriers by comparing and analyzing the genomic sequences of screening samples, and conducting clinical trials to verify the applicability and reliability of the method.

Benefits of technology

Improve screening efficiency and accuracy, help couples of childbearing age make informed fertility decisions, reduce the incidence of single-gene genetic diseases, reduce family and social burdens, and promote early diagnosis and management of genetic diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a research and development method for a screening product of a high-incidence single-gene recessive genetic disease carrier in an infertility period, and the method comprises the following steps: 1, collecting literature and database information related to a screened disease, and determining a target disease type; 2, designing a specific primer, carrying out PCR amplification, and detecting by combining a high-throughput sequencing technology; 3, building a data analysis platform, and identifying a potential carrier by comparing and analyzing the genome sequence of the screening sample; 4, carrying out a clinical test, and verifying the applicability and reliability of the method in different crowds; through screening, potential genetic risks can be effectively identified, and farmers at childbearing age are helped to make more intelligent childbearing decisions, so that the occurrence rate of single-gene genetic diseases is reduced, and the health level of newborns is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field related to power distribution equipment, and specifically relates to a method for developing a product for screening carriers of high-incidence single-gene recessive genetic diseases during the peri-pregnancy period. Background Art

[0002] Screening for carriers of high-incidence single-gene recessive genetic diseases during the peri-pregnancy period is an important part of modern genetics and reproductive health. It aims to identify individuals who may carry genetic disease genes at an early stage, especially those who are carriers of recessive genetic diseases, to help them make more informed reproductive decisions. The development and implementation of this technology involves the integration of interdisciplinary technologies, including molecular biology, bioinformatics, genetic counseling, and clinical medicine.

[0003] Traditional carrier screening methods are inefficient when applied to pregnant women and there is a certain rate of false identification. Summary of the invention

[0004] The purpose of the present invention is to provide a method for developing a screening product for carriers of high-incidence single-gene recessive genetic diseases during the peri-pregnancy period, so as to solve the problems raised in the above-mentioned background technology.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] A method for developing a product for screening carriers of high-incidence single-gene recessive genetic diseases during the peri-pregnancy period, the method steps are as follows:

[0007] Step 1: Collect literature and database information related to the disease to be screened and determine the target disease;

[0008] Step 2: Design specific primers, perform PCR amplification, and detect using high-throughput sequencing technology;

[0009] Step 3: Build a data analysis platform to identify potential carriers by comparing and analyzing the genome sequences of screening samples;

[0010] Step 4: Conduct clinical trials to verify the applicability and reliability of this method in different populations.

[0011] Preferably, the specific process of step 1 above is as follows:

[0012] S1. Identify target genetic diseases

[0013] Select a common single gene recessive genetic disease, such as cystic fibrosis, thalassemia or spinal muscular atrophy, and on this basis, identify the specific genes related to the genetic disease (such as CFTR, HBB, SMN1, etc.);

[0014] S2. Mutation site screening

[0015] 2.1 Literature survey and data collection

[0016] Collect literature on the target genetic disease and search for mutation site information related to the disease;

[0017] Use public databases (e.g., dbSNP, ClinVar) to integrate information, especially high-frequency mutations and pathogenic mutations;

[0018] 2.2 Determination of key mutation sites

[0019] Screen important mutation sites associated with clinical phenotypes, including efficacy mutations and common carrier mutations.

[0020] Ensure that the incidence of selected mutation sites in different populations is well documented.

[0021] S3. Design specific primers

[0022] 3.1 Primer design

[0023] Combined with gene sequence information, use online software (such as Primer3, OligoCalc) to design specific primers;

[0024] Primers designed should contain:

[0025] High specificity (avoid nonspecific binding as much as possible);

[0026] Suitable annealing temperature (usually between 55°C and 65°C);

[0027] The GC content of the control primers was between 40% and 60%;

[0028] 3.2 Primer optimization

[0029] Verify the amplification efficiency of primers through experiments to ensure ideal results in PCR experiments;

[0030] S4. Sample processing

[0031] 4.1 Sample Collection

[0032] Determine the appropriate sample type (e.g., blood, saliva, or buccal cells);

[0033] Ensure that the ethical collection and handling of samples complies with relevant laws and regulations;

[0034] 4.2 DNA extraction

[0035] Extract high-quality genomic DNA using a commercial DNA extraction kit or standardized laboratory methods;

[0036] S5. PCR amplification

[0037] 5.1 Reaction system

[0038] Prepare PCR reaction mixture, including specific primers, DNA template, DNA polymerase, dNTPs, and buffer;

[0039] 5.2 PCR Cycling Conditions

[0040] Optimize PCR cycling conditions, including denaturation, annealing, and extension steps. Consider using a thermal cycler for multiplex PCR to amplify multiple target sites simultaneously.

[0041] S6. High-throughput sequencing

[0042] 6.1 Library construction

[0043] The PCR product is used to construct a library, and a library construction kit suitable for a high-throughput sequencing platform may be used;

[0044] Amplifying the library to obtain a base pair length suitable for subsequent sequencing;

[0045] 6.2 Sequencing

[0046] Select a suitable high-throughput sequencing platform (such as Illumina, Ion Torrent, etc.) to sequence the constructed library.

[0047] S7. Data Analysis

[0048] 7.1 Raw Data Processing

[0049] Use dedicated analysis software to perform quality control on the obtained sequencing data (such as Trimmomatic) and remove low-quality sequences;

[0050] 7.2 Mutation identification

[0051] Use bioinformatics tools (such as GATK) to detect variants and identify key mutation sites associated with target diseases;

[0052] Compare with the reference genome and annotate the nature of the mutation (missense, nonsense, insertion, deletion, etc.);

[0053] 7.3 Statistical analysis

[0054] Conduct statistical analysis on the test results to calculate the frequency of mutations and the proportion of carriers;

[0055] S8. Interpretation and feedback of results

[0056] 8.1 Results Report

[0057] Based on the analysis results, a detailed test report is prepared, including mutation information, carrier risk assessment and clinical recommendations.

[0058] 8.2 Follow-up and consultation

[0059] Provide genetic counseling services to help users understand the results and give recommendations for follow-up testing or family screening.

[0060] S9. Quality Control

[0061] Establish quality control standards for each step to ensure the repeatability and reliability of the method, including sample processing, PCR amplification, sequencing and data analysis.

[0062] Preferably, the specific process of the above step 2 is as follows:

[0063] S1. Determine the target gene and mutation site

[0064] Select the key gene for the single gene recessive genetic disease to be tested (e.g. CFTR, HBB, SMN1, etc.) Analyze and record the mutation sites related to the disease based on literature and databases (e.g. ClinVar, dbSNP).

[0065] S2. Design specific primers

[0066] 2.1 Using primer design tools

[0067] When designing primers using online tools (e.g., Primer3, OligoCalc), consider the following factors:

[0068] The recommended primer length is between 18 and 25 bases.

[0069] The annealing temperature (Tm) should be between 55°C and 65°C, preferably within 2°C.

[0070] The GC content should be between 40% and 60%.

[0071] Avoid primer dimers, hairpin structures, and nonspecific binding to target sequences.

[0072] 2.2 Example Primer Design

[0073] Assume that the target gene you choose is HBB (β-globin gene), which is associated with thalassemia. You can design multiple specific primers for common mutations in the HBB gene (such as c.20A>T).

[0074] Primer 1 (forward): 5'-ATGGTGACATACAACTTTG-3'

[0075] Primer 2 (reverse): 5'-TCTGCTGCCCACTTGTTAC-3'

[0076] 2.3 Verification of primer specificity

[0077] Use the BLAST tool to check the specificity of the primers to other regions in the genome to ensure that the primers bind only to the target gene.

[0078] S3. PCR amplification

[0079] 3.1 PCR reaction system

[0080] In one PCR reaction, prepare the following composition (volume 100 μL):

[0081] 10x PCR buffer: 10 μL

[0082] dNTP mixture (0.2 mM each): 2 μL

[0083] Upstream primer (10 μM): 1 μL

[0084] Downstream primer (10μM): 1μL

[0085] DNA polymerase (such as Taq polymerase): 0.5 μL

[0086] DNA template to be amplified: 1-10 μL

[0087] Ultrapure water: up to 100 μL

[0088] 3.2 PCR Cycling Conditions

[0089] Initial denaturation: 95°C, 2 minutes

[0090] Denaturation: 95°C, 30 seconds

[0091] Annealing: set at 60°C, 30 seconds (optimized according to the Tm of the primers)

[0092] Extension: 72°C, 1 minute (approximately 30 seconds per 1000 bp)

[0093] Number of cycles: 30 times

[0094] Final extension: 72°C, 5 minutes

[0095] S4. High-throughput sequencing

[0096] 4.1 Library construction

[0097] The PCR amplified product is purified by agarose gel electrophoresis (column purification may be used).

[0098] Use a library construction kit (such as Illumina Nextera or TruSeq, etc.) to convert the PCR amplification product into a sequencing library:

[0099] The PCR products were digested, adapters were added, amplified and purified.

[0100] 4.2 Sequencing

[0101] The constructed library is sequenced according to the standards of the sequencing platform (such as Illumina, Ion Torrent, etc.).

[0102] Depending on the sequencing platform chosen, select an appropriate read length and sequencing depth.

[0103] S5. Data Analysis

[0104] 5.1 Sequencing data processing

[0105] Use bioinformatics software (such as FastQC) to perform quality control on raw sequencing data and remove low-quality sequences and adapter sequences.

[0106] 5.2 Mutation Detection

[0107] Use variant detection tools (such as GATK, FreeBayes, etc.) to identify mutations in samples.

[0108] The mutation is compared with the predicted mutation site database to confirm its relevance to the target disease.

[0109] S6. Interpretation and reporting of results

[0110] 6.1 Results Report

[0111] Summarize all detected mutation information and assess the pathogenicity of the mutation (according to ClinVar or other databases).

[0112] Provide a clear explanation of the results, and genetic counseling may be needed to help understand the results.

[0113] Preferably, the specific process of step three above is as follows:

[0114] S1. Platform architecture design

[0115] 1.1 Hardware and Software Environment

[0116] Server: High-performance computing server or cloud computing platform (such as AWS, Google Cloud) to process large-scale data.

[0117] Operating system: Linux (such as Ubuntu or CentOS) to support bioinformatics software.

[0118] Programming Languages: Python and R for analysis and visualization.

[0119] 1.2 Required Software and Tools

[0120] Alignment tools: such as BWA (Burrows-Wheeler Aligner) or Bowtie2, used to align sequencing reads to a reference genome.

[0121] Variant detection tools: such as GATK (Genome Analysis Toolkit) or FreeBayes, used to identify variants.

[0122] Annotation tools: such as ANNOVAR or Variant Effect Predictor (VEP), used to annotate the functional effects of mutations.

[0123] database:

[0124] Human genome reference sequence: Download from UCSC Genome Browser or Ensembl.

[0125] Known mutation databases: such as dbSNP and ClinVar, used to compare known pathogenic mutations.

[0126] S2. Data Analysis Process

[0127] 2.1 Data Preprocessing

[0128] Quality control: The raw sequencing data were quality checked using the FastQC tool, and low-quality sequences and adapters were removed using Trimmomatic.

[0129] Comparison:

[0130] Use BWA or Bowtie2 to align the cleaned sequences and generate an alignment file (BAM file).

[0131] Duplicate removal: PCR duplicates were removed using the Picard tool to reduce the false positive rate.

[0132] 2.2 Mutation Detection

[0133] Call variants: Use GATK or FreeBayes to call SNP and Indel variants from the deduplicated BAM files.

[0134] Filter variants: Apply standard filters to variant results to identify potential pathogenic variants.

[0135] 2.3 Mutation Annotation

[0136] ANNOVAR or VEP was used to annotate the selected variants and determine their potential clinical relevance.

[0137] 2.4 Screening for potential carriers

[0138] Compare known pathogenic mutations: Compare annotated variants with pathogenic mutation databases (such as ClinVar) to screen samples carrying pathogenic mutations.

[0139] Risk assessment: Evaluate the pathogenicity of the mutations in the sample and their impact on potential carriers.

[0140] S3, Data Visualization and Reporting

[0141] Use R language (ggplot2, shiny) or Python (matplotlib, seaborn) to visualize data and display information such as mutation distribution and sample characteristics.

[0142] Generates a detailed test report including mutation information, carrier risk assessment, and clinical recommendations.

[0143] S4. Results and Feedback

[0144] Feedback analysis results to clinicians or researchers to discuss management of potential carriers and follow-up testing recommendations.

[0145] Genetic counseling services were provided to participants to help understand the test results.

[0146] S5. Quality Control and Update

[0147] The database is updated regularly to ensure that the latest mutation information is captured.

[0148] Strengthen quality control steps to ensure the accuracy and reliability of results.

[0149] Through the above steps, you can build an efficient and systematic data analysis platform to identify potential gene carriers. This process is crucial in the screening and management of genetic diseases.

[0150] Preferably, the specific process of step 4 above is as follows:

[0151] S1. Clinical trial design

[0152] 1.1 Establishing research objectives

[0153] Primary objectives: To validate the sensitivity, specificity, positive predictive value, and negative predictive value of the new method.

[0154] Secondary objectives: To evaluate the applicability of the method in different populations (e.g., different races, ethnicities, age groups, etc.).

[0155] 1.2 Sample selection

[0156] Inclusion criteria: Select participants who meet specific population characteristics (such as medical history, genetic background, etc.). For example, select those with a high-risk family history or known disease carriers.

[0157] Exclusion criteria: Patients with other genetic diseases or syndromes were excluded to ensure the accuracy of the results.

[0158] 1.3 Sample size calculation

[0159] Statistical methods are used to calculate sample size to ensure the statistical significance and reliability of the trial results.

[0160] S2. Implementation of the test

[0161] 2.1 Recruiting participants

[0162] Develop a clear recruitment plan to ensure that the necessary sample can be obtained.

[0163] Recruitment was conducted through hospitals, community outreach, and genetic counseling centers to ensure representativeness of the sample.

[0164] 2.2 Collecting samples

[0165] Collect DNA samples (such as blood, saliva) from participants and ensure that the quality and storage conditions of the samples meet the standards.

[0166] 2.3 Data Collection

[0167] Define methods for data collection, including detailed medical history, family history, and other relevant information.

[0168] Design questionnaires or interviews to collect relevant information from participants for subsequent analysis.

[0169] S3. Implement testing

[0170] 3.1 Data Analysis

[0171] The collected samples were subjected to genome sequence analysis using the established data analysis platform.

[0172] Alignment, variant calling, and annotation were performed as described previously.

[0173] 3.2 Results Evaluation

[0174] Test results were statistically analyzed and compared with predefined standards.

[0175] To assess differences in test results among different populations and the implications for early screening and intervention.

[0176] S4. Data analysis and statistics

[0177] 4.1 Statistical methods

[0178] Use appropriate statistical tools for data analysis.

[0179] The sensitivity, specificity, positive predictive value, and negative predictive value of the results in different populations were compared using relevant statistical methods such as the Chi-square test.

[0180] 4.2 Interpretation of results

[0181] The applicability of the method in different populations is discussed and compared with existing literature.

[0182] Identify factors that may have influenced the results.

[0183] S5. Reporting and Release

[0184] 5.1 Writing a research report

[0185] Organize the research process, results and discussions, and write a complete clinical trial report.

[0186] Emphasize the reliability of the method and its applicability in different populations.

[0187] 5.2 Published Papers

[0188] Publish research results in relevant academic journals to share experiences and discoveries.

[0189] Attend relevant academic conferences to present research results and obtain feedback.

[0190] S6. Promotion of clinical application

[0191] 6.1 Providing clinical advice

[0192] Based on the research results, provide guidance for clinicians and genetic counselors.

[0193] Develop specific clinical application guidelines to aid in genetic disease screening and management.

[0194] 6.2 Monitoring and Feedback

[0195] Continuously monitor the effectiveness of the methods and collect feedback for continuous improvement.

[0196] Regularly update testing procedures and analytical methods to ensure they adapt to new scientific advances.

[0197] S7. Ethics and Compliance

[0198] Ensure that clinical trials follow the guidance of the ethics committee and local laws and regulations, and obtain informed consent from patients.

[0199] Regularly review the trial process to ensure that patient rights are protected.

[0200] Compared with the prior art, the present invention provides a method for developing a product for screening carriers of high-incidence single-gene recessive genetic diseases during the peri-pregnancy period, which has the following beneficial effects:

[0201] Improve reproductive health: Screening can effectively identify potential genetic risks and help couples of childbearing age make more informed reproductive decisions, thereby reducing the incidence of single gene genetic diseases and improving the health of newborns;

[0202] Prevention and control of birth defects: Expanded carrier screening technology can help prevent birth defects caused by autosomal recessive or X-linked genetic diseases, especially when screening is performed before or during early pregnancy, so that intervention measures can be taken early;

[0203] Reduce the burden on families and society: Single-gene genetic diseases often lack effective treatments. Preventing the occurrence of these diseases can reduce the economic and psychological burden on families and relieve the pressure on social medical resources;

[0204] Promoting early diagnosis and management of genetic diseases: Screening can help doctors provide targeted genetic counseling and prenatal diagnosis for high-risk couples, promoting diagnostic testing and subsequent precision counseling;

[0205] Improve public health awareness: With the popularization of screening technology and the release of expert consensus, the public's awareness of genetic diseases will increase, promoting health education and the implementation of preventive measures;

[0206] Technological innovation and industrial development: The research and development of peri-pregnancy screening products has promoted the innovation of related technologies such as gene sequencing and bioinformatics, and promoted the development of the genetic disease testing service industry;

[0207] Data support and decision-making basis: Through large-scale screening projects, data on the carrier status of the Chinese population of childbearing age can be collected, providing strong data support and decision-making basis for the prevention and control of birth defects;

[0208] Personalized and precise services: With the advancement of technology, screening products can be more personalized and precise to meet the needs of different groups of people and improve the applicability and effectiveness of screening. DETAILED DESCRIPTION

[0209] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0210] The present invention provides a technical solution:

[0211] A method for developing a product for screening carriers of high-incidence single-gene recessive genetic diseases during the peri-pregnancy period, the method steps are as follows:

[0212] Step 1: Collect literature and database information related to the disease to be screened and determine the target disease;

[0213] Step 2: Design specific primers, perform PCR amplification, and detect using high-throughput sequencing technology;

[0214] Step 3: Build a data analysis platform to identify potential carriers by comparing and analyzing the genome sequences of screening samples;

[0215] Step 4: Conduct clinical trials to verify the applicability and reliability of this method in different populations.

[0216] The specific process of step 1 above is as follows:

[0217] S1. Identify target genetic diseases

[0218] Select a common single gene recessive genetic disease, such as cystic fibrosis, thalassemia or spinal muscular atrophy, and on this basis, identify the specific genes related to the genetic disease (such as CFTR, HBB, SMN1, etc.);

[0219] S2. Mutation site screening

[0220] 2.1 Literature survey and data collection

[0221] Collect literature on the target genetic disease and search for mutation site information related to the disease;

[0222] Use public databases (e.g., dbSNP, ClinVar) to integrate information, especially high-frequency mutations and pathogenic mutations;

[0223] 2.2 Determination of key mutation sites

[0224] Screen important mutation sites associated with clinical phenotypes, including efficacy mutations and common carrier mutations.

[0225] Ensure that the incidence of selected mutation sites in different populations is well documented.

[0226] S3. Design specific primers

[0227] 3.1 Primer design

[0228] Combined with gene sequence information, use online software (such as Primer3, OligoCalc) to design specific primers;

[0229] Primers designed should contain:

[0230] High specificity (avoid nonspecific binding as much as possible);

[0231] Suitable annealing temperature (usually between 55°C and 65°C);

[0232] The GC content of the control primers was between 40% and 60%;

[0233] 3.2 Primer optimization

[0234] Verify the amplification efficiency of primers through experiments to ensure ideal results in PCR experiments;

[0235] S4. Sample processing

[0236] 4.1 Sample Collection

[0237] Determine the appropriate sample type (e.g., blood, saliva, or buccal cells);

[0238] Ensure that the ethical collection and handling of samples complies with relevant laws and regulations;

[0239] 4.2 DNA extraction

[0240] Extract high-quality genomic DNA using a commercial DNA extraction kit or standardized laboratory methods;

[0241] S5. PCR amplification

[0242] 5.1 Reaction system

[0243] Prepare PCR reaction mixture, including specific primers, DNA template, DNA polymerase, dNTPs, and buffer;

[0244] 5.2 PCR Cycling Conditions

[0245] Optimize PCR cycling conditions, including denaturation, annealing, and extension steps. Consider using a thermal cycler for multiplex PCR to amplify multiple target sites simultaneously.

[0246] S6. High-throughput sequencing

[0247] 6.1 Library construction

[0248] The PCR product is used to construct a library, and a library construction kit suitable for a high-throughput sequencing platform may be used;

[0249] Amplifying the library to obtain a base pair length suitable for subsequent sequencing;

[0250] 6.2 Sequencing

[0251] Select a suitable high-throughput sequencing platform (such as Illumina, Ion Torrent, etc.) to sequence the constructed library.

[0252] S7. Data Analysis

[0253] 7.1 Raw Data Processing

[0254] Use dedicated analysis software to perform quality control on the obtained sequencing data (such as Trimmomatic) and remove low-quality sequences;

[0255] 7.2 Mutation identification

[0256] Use bioinformatics tools (such as GATK) to detect variants and identify key mutation sites associated with target diseases;

[0257] Compare with the reference genome and annotate the nature of the mutation (missense, nonsense, insertion, deletion, etc.);

[0258] 7.3 Statistical analysis

[0259] Conduct statistical analysis on the test results to calculate the frequency of mutations and the proportion of carriers;

[0260] S8. Interpretation and feedback of results

[0261] 8.1 Results Report

[0262] Based on the analysis results, a detailed test report is prepared, including mutation information, carrier risk assessment and clinical recommendations.

[0263] 8.2 Follow-up and consultation

[0264] Provide genetic counseling services to help users understand the results and give recommendations for follow-up testing or family screening.

[0265] S9. Quality Control

[0266] Establish quality control standards for each step to ensure the repeatability and reliability of the method, including sample processing, PCR amplification, sequencing and data analysis.

[0267] The specific process of step 2 above is as follows:

[0268] S1. Determine the target gene and mutation site

[0269] Select the key gene for the single gene recessive genetic disease to be tested (e.g. CFTR, HBB, SMN1, etc.) Analyze and record the mutation sites related to the disease based on literature and databases (e.g. ClinVar, dbSNP).

[0270] S2. Design specific primers

[0271] 2.1 Using primer design tools

[0272] When designing primers using online tools (e.g., Primer3, OligoCalc), consider the following factors:

[0273] The recommended primer length is between 18 and 25 bases.

[0274] The annealing temperature (Tm) should be between 55°C and 65°C, preferably within 2°C.

[0275] The GC content should be between 40% and 60%.

[0276] Avoid primer dimers, hairpin structures, and nonspecific binding to target sequences.

[0277] 2.2 Example Primer Design

[0278] Assume that the target gene you choose is HBB (β-globin gene), which is associated with thalassemia. You can design multiple specific primers for common mutations in the HBB gene (such as c.20A>T).

[0279] Primer 1 (forward): 5'-ATGGTGACATACAACTTTG-3'

[0280] Primer 2 (reverse): 5'-TCTGCTGCCCACTTGTTAC-3'

[0281] 2.3 Verification of primer specificity

[0282] Use the BLAST tool to check the specificity of the primers to other regions in the genome to ensure that the primers bind only to the target gene.

[0283] S3. PCR amplification

[0284] 3.1 PCR reaction system

[0285] In one PCR reaction, prepare the following composition (volume 100 μL):

[0286] 10x PCR buffer: 10 μL

[0287] dNTP mixture (0.2 mM each): 2 μL

[0288] Upstream primer (10 μM): 1 μL

[0289] Downstream primer (10μM): 1μL

[0290] DNA polymerase (such as Taq polymerase): 0.5 μL

[0291] DNA template to be amplified: 1-10 μL

[0292] Ultrapure water: up to 100 μL

[0293] 3.2 PCR Cycling Conditions

[0294] Initial denaturation: 95°C, 2 minutes

[0295] Denaturation: 95°C, 30 seconds

[0296] Annealing: set at 60°C, 30 seconds (optimized according to the Tm of the primers)

[0297] Extension: 72°C, 1 minute (approximately 30 seconds per 1000 bp)

[0298] Number of cycles: 30 times

[0299] Final extension: 72°C, 5 minutes

[0300] S4. High-throughput sequencing

[0301] 4.1 Library construction

[0302] The PCR amplified product is purified by agarose gel electrophoresis (column purification may be used).

[0303] Use a library construction kit (such as Illumina Nextera or TruSeq, etc.) to convert the PCR amplification product into a sequencing library:

[0304] The PCR products were digested, adapters were added, amplified and purified.

[0305] 4.2 Sequencing

[0306] The constructed library is sequenced according to the standards of the sequencing platform (such as Illumina, Ion Torrent, etc.).

[0307] Depending on the sequencing platform chosen, select an appropriate read length and sequencing depth.

[0308] S5. Data Analysis

[0309] 5.1 Sequencing data processing

[0310] Use bioinformatics software (such as FastQC) to perform quality control on raw sequencing data and remove low-quality sequences and adapter sequences.

[0311] 5.2 Mutation Detection

[0312] Use variant detection tools (such as GATK, FreeBayes, etc.) to identify mutations in samples.

[0313] The mutation is compared with the predicted mutation site database to confirm its relevance to the target disease.

[0314] S6. Interpretation and reporting of results

[0315] 6.1 Results Report

[0316] Summarize all detected mutation information and assess the pathogenicity of the mutation (according to ClinVar or other databases).

[0317] Provide a clear explanation of the results, and genetic counseling may be needed to help understand the results.

[0318] The specific process of step three above is as follows:

[0319] S1. Platform architecture design

[0320] 1.1 Hardware and Software Environment

[0321] Server: High-performance computing server or cloud computing platform (such as AWS, Google Cloud) to process large-scale data.

[0322] Operating system: Linux (such as Ubuntu or CentOS) to support bioinformatics software.

[0323] Programming Languages: Python and R for analysis and visualization.

[0324] 1.2 Required Software and Tools

[0325] Alignment tools: such as BWA (Burrows-Wheeler Aligner) or Bowtie2, used to align sequencing reads to a reference genome.

[0326] Variant detection tools: such as GATK (Genome Analysis Toolkit) or FreeBayes, used to identify variants.

[0327] Annotation tools: such as ANNOVAR or Variant Effect Predictor (VEP), used to annotate the functional effects of mutations.

[0328] database:

[0329] Human genome reference sequence: Download from UCSC Genome Browser or Ensembl.

[0330] Known mutation databases: such as dbSNP and ClinVar, used to compare known pathogenic mutations.

[0331] S2. Data Analysis Process

[0332] 2.1 Data Preprocessing

[0333] Quality control: The raw sequencing data were quality checked using the FastQC tool, and low-quality sequences and adapters were removed using Trimmomatic.

[0334] Comparison:

[0335] Use BWA or Bowtie2 to align the cleaned sequences and generate an alignment file (BAM file).

[0336] Duplicate removal: PCR duplicates were removed using the Picard tool to reduce the false positive rate.

[0337] 2.2 Mutation Detection

[0338] Call variants: Use GATK or FreeBayes to call SNP and Indel variants from the deduplicated BAM files.

[0339] Filter variants: Apply standard filters to variant results to identify potential pathogenic variants.

[0340] 2.3 Mutation Annotation

[0341] ANNOVAR or VEP was used to annotate the selected variants and determine their potential clinical relevance.

[0342] 2.4 Screening for potential carriers

[0343] Compare known pathogenic mutations: Compare annotated variants with pathogenic mutation databases (such as ClinVar) to screen samples carrying pathogenic mutations.

[0344] Risk assessment: Evaluate the pathogenicity of the mutations in the sample and their impact on potential carriers.

[0345] S3, Data Visualization and Reporting

[0346] Use R language (ggplot2, shiny) or Python (matplotlib, seaborn) to visualize data and display information such as mutation distribution and sample characteristics.

[0347] Generates a detailed test report including mutation information, carrier risk assessment, and clinical recommendations.

[0348] S4. Results and Feedback

[0349] Feedback analysis results to clinicians or researchers to discuss management of potential carriers and follow-up testing recommendations.

[0350] Genetic counseling services were provided to participants to help understand the test results.

[0351] S5. Quality Control and Update

[0352] The database is updated regularly to ensure that the latest mutation information is captured.

[0353] Strengthen quality control steps to ensure the accuracy and reliability of results.

[0354] Through the above steps, you can build an efficient and systematic data analysis platform to identify potential gene carriers. This process is crucial in the screening and management of genetic diseases.

[0355] The specific process of step 4 above is as follows:

[0356] S1. Clinical trial design

[0357] 1.1 Establishing research objectives

[0358] Primary objectives: To validate the sensitivity, specificity, positive predictive value, and negative predictive value of the new method.

[0359] Secondary objectives: To evaluate the applicability of the method in different populations (e.g., different races, ethnicities, age groups, etc.).

[0360] 1.2 Sample selection

[0361] Inclusion criteria: Select participants who meet specific population characteristics (such as medical history, genetic background, etc.). For example, select those with a high-risk family history or known disease carriers.

[0362] Exclusion criteria: Patients with other genetic diseases or syndromes were excluded to ensure the accuracy of the results.

[0363] 1.3 Sample size calculation

[0364] Statistical methods are used to calculate sample size to ensure the statistical significance and reliability of the trial results.

[0365] S2. Implementation of the test

[0366] 2.1 Recruiting participants

[0367] Develop a clear recruitment plan to ensure that the necessary sample can be obtained.

[0368] Recruitment was conducted through hospitals, community outreach, and genetic counseling centers to ensure representativeness of the sample.

[0369] 2.2 Collecting samples

[0370] Collect DNA samples (such as blood, saliva) from participants and ensure that the quality and storage conditions of the samples meet the standards.

[0371] 2.3 Data Collection

[0372] Define methods for data collection, including detailed medical history, family history, and other relevant information.

[0373] Design questionnaires or interviews to collect relevant information from participants for subsequent analysis.

[0374] S3. Implement testing

[0375] 3.1 Data Analysis

[0376] The collected samples were subjected to genome sequence analysis using the established data analysis platform.

[0377] Alignment, variant calling, and annotation were performed as described previously.

[0378] 3.2 Results Evaluation

[0379] Test results were statistically analyzed and compared with predefined standards.

[0380] To assess differences in test results among different populations and the implications for early screening and intervention.

[0381] S4. Data analysis and statistics

[0382] 4.1 Statistical methods

[0383] Use appropriate statistical tools (such as SPSS, R, etc.) for data analysis.

[0384] The sensitivity, specificity, positive predictive value, and negative predictive value of the results in different populations were compared using relevant statistical methods such as the Chi-square test.

[0385] 4.2 Interpretation of results

[0386] The applicability of the method in different populations is discussed and compared with existing literature.

[0387] Identify factors that may influence the results (e.g. genetic background, environmental factors, etc.).

[0388] S5. Reporting and Release

[0389] 5.1 Writing a research report

[0390] Organize the research process, results and discussions, and write a complete clinical trial report.

[0391] Emphasize the reliability of the method and its applicability in different populations.

[0392] 5.2 Published Papers

[0393] Publish research results in relevant academic journals to share experiences and discoveries.

[0394] Attend relevant academic conferences to present research results and obtain feedback.

[0395] S6. Promotion of clinical application

[0396] 6.1 Providing clinical advice

[0397] Based on the research results, provide guidance for clinicians and genetic counselors.

[0398] Develop specific clinical application guidelines to aid in genetic disease screening and management.

[0399] 6.2 Monitoring and Feedback

[0400] Continuously monitor the effectiveness of the methods and collect feedback for continuous improvement.

[0401] Regularly update testing procedures and analytical methods to ensure they adapt to new scientific advances.

[0402] S7. Ethics and Compliance

[0403] Ensure that clinical trials follow the guidance of the ethics committee and local laws and regulations, and obtain informed consent from patients.

[0404] Regularly review the trial process to ensure that patient rights are protected.

[0405] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for developing a product for screening carriers of high-incidence single-gene recessive genetic diseases during the peri-pregnancy period, characterized by: The steps are as follows: Step 1: Collect literature and database information related to the disease to be screened and determine the target disease; Step 2: Design specific primers, perform PCR amplification, and detect using high-throughput sequencing technology; Step 3: Build a data analysis platform to identify potential carriers by comparing and analyzing the genome sequences of screening samples; Step 4: Conduct clinical trials to verify the applicability and reliability of this method in different populations.

2. The method for developing a product for screening carriers of a high incidence of single gene recessive genetic diseases during the peri-pregnancy period according to claim 1, characterized in that the specific process of the above step 1 is as follows: S1. Identify target genetic diseases Select a common single gene recessive genetic disease, such as cystic fibrosis, thalassemia or spinal muscular atrophy, and on this basis, identify the specific gene associated with the genetic disease; S2. Mutation site screening 2.1 Literature survey and data collection Collect literature on the target genetic disease and search for mutation site information related to the disease; Use public databases to integrate information, especially high-frequency and pathogenic mutations; 2.2 Determination of key mutation sites Screening for important mutation sites associated with clinical phenotypes, including efficacy mutations and common carrier mutations; Ensure that the incidence of selected mutation sites in different populations is well documented; S3. Design specific primers 3.1 Primer design Combined with gene sequence information, specific primers were designed using online software; Primers designed should contain: High specificity; Suitable annealing temperature; The GC content of the control primers was between 40% and 60%; 3.2 Primer optimization Verify the amplification efficiency of primers through experiments to ensure ideal results in PCR experiments; S4. Sample processing 4.1 Sample Collection Determine the appropriate sample type; Ensure that the ethical collection and handling of samples complies with relevant laws and regulations; 4.2 DNA extraction Extract high-quality genomic DNA using a commercial DNA extraction kit or standardized laboratory methods; S5. PCR amplification 5.1 Reaction system Prepare PCR reaction mixture, including specific primers, DNA template, DNA polymerase, dNTPs, and buffer; 5.2 PCR Cycling Conditions Optimize PCR cycling conditions, including denaturation, annealing, and extension steps, and consider using a thermal cycler for multiplex PCR to simultaneously amplify multiple target loci; S6. High-throughput sequencing 6.1 Library construction The PCR products were used to construct libraries using a library construction kit suitable for high-throughput sequencing platforms; Amplifying the library to obtain a base pair length suitable for subsequent sequencing; 6.2 Sequencing Select a suitable high-throughput sequencing platform to sequence the constructed library; S7. Data Analysis 7.1 Raw Data Processing Use dedicated analysis software to perform quality control on the obtained sequencing data and remove low-quality sequences; 7.2 Mutation identification Use bioinformatics tools to detect mutations and identify key mutation sites associated with target diseases; Compare with the reference genome and annotate the nature of the mutation; 7.3 Statistical analysis Conduct statistical analysis on the test results to calculate the frequency of mutations and the proportion of carriers; S8. Interpretation and feedback of results 8.1 Results Report Prepare a detailed test report based on the analysis results, including mutation information, carrier risk assessment and clinical recommendations; 8.2 Follow-up and consultation Provide genetic counseling services to help users understand the results and give recommendations for follow-up testing or family screening; S9. Quality Control Establish quality control standards for each step to ensure the repeatability and reliability of the method, including sample processing, PCR amplification, sequencing and data analysis.

3. The method for developing a product for screening carriers of a high incidence of single gene recessive genetic diseases during the peri-pregnancy period according to claim 1, characterized in that: The specific process of step 2 above is as follows: S1. Determine the target gene and mutation site Select the key gene for the single gene recessive genetic disease to be tested; analyze and record the mutation sites related to the disease based on literature and databases; S2. Design specific primers 2.1 Using primer design tools When designing primers using online tools, consider the following factors: The recommended length of primers is between 18 and 25 bases; The annealing temperature (Tm) should be between 55°C and 65°C, preferably within 2°C; The GC content should be between 40% and 60% as much as possible; Avoid primer dimers, hairpin structures, and non-specific binding to target sequences; 2.2 Example Primer Design Assume that the target gene you choose is HBB, which is associated with thalassemia. You can design multiple specific primers for common mutations in the HBB gene; Primer 1 (forward): 5'-ATGGTGACATACAACTTTG-3' Primer 2 (reverse): 5'-TCTGCTGCCCACTTGTTAC-3' 2.3 Verification of primer specificity Use BLAST tools to check the specificity of primers to other regions in the genome to ensure that the primers bind only to the target gene; S3. PCR amplification 3.1 PCR reaction system In one PCR reaction, prepare the following: 10x PCR buffer: 10 μL dNTP mix, 0.2 mM each: 2 μL Upstream primer: 1 μL Downstream primer: 1 μL DNA polymerase: 0.5 μL DNA template to be amplified: 1-10 μL Ultrapure water: up to 100 μL 3.2 PCR Cycling Conditions Initial denaturation: 95°C, 2 minutes Denaturation: 95°C, 30 seconds Annealing: set at 60°C, 30 seconds Extension: 72°C, 1 min Number of cycles: 30 times Final extension: 72°C, 5 minutes S4. High-throughput sequencing 4.1 Library construction The PCR amplified product is purified by agarose gel electrophoresis (column purification may be used). Use a library construction kit to convert the PCR amplification product into a sequencing library: Perform enzyme digestion, linker addition, amplification and purification on PCR products; 4.2 Sequencing Sequence the constructed library according to the standards of the sequencing platform; Depending on the sequencing platform selected, choose the appropriate read length and sequencing depth; S5. Data Analysis 5.1 Sequencing data processing Use bioinformatics software to perform quality control on raw sequencing data and remove low-quality sequences and adapter sequences; 5.2 Mutation Detection Use variant detection tools to identify mutations in samples; Compare the mutation with the predicted mutation site database to confirm its relevance to the target disease; S6. Interpretation and reporting of results 6.1 Results Report Summarize all detected mutation information and assess the pathogenicity of the mutation; Provide a clear explanation of the results, and genetic counseling may be needed to help understand the results.

4. The method for developing a product for screening carriers of a high incidence of single gene recessive genetic diseases during the peri-pregnancy period according to claim 1, characterized in that: The specific process of step 3 above is as follows: S1. Platform architecture design 1.1 Hardware and Software Environment Server: High-performance computing server or cloud computing platform to process large-scale data; Operating system: Linux to support bioinformatics software; Programming languages: Python and R for analysis and visualization; 1.2 Required Software and Tools Alignment tools: such as BWA or Bowtie2, used to align sequencing reads to a reference genome; Variant detection tools: such as GATK (Genome Analysis Toolkit) or FreeBayes, used to identify variants; Annotation tools: such as ANNOVAR or Variant Effect Predictor (VEP), used to annotate the functional effects of mutations; database: Human genome reference sequence: downloaded from UCSC Genome Browser or Ensembl; Known mutation databases: such as dbSNP and ClinVar, used to compare known pathogenic mutations; S2. Data Analysis Process 2.1 Data Preprocessing Quality control: FastQC tool was used to check the quality of raw sequencing data, and Trimmomatic was used to remove low-quality sequences and adapters; Comparison: Use BWA or Bowtie2 to align the cleaned sequences and generate an alignment file; Remove duplicates: Use the Picard tool to remove PCR duplicates to reduce the false positive rate; 2.2 Mutation Detection Call variants: Use GATK or FreeBayes to call SNP and Indel variants from the deduplicated BAM files; Filter variants: Apply standard filters to variant results to identify potential pathogenic variants; 2.3 Mutation Annotation Use ANNOVAR or VEP to annotate the selected variants and determine their potential clinical relevance; 2.4 Screening for potential carriers Compare known pathogenic mutations: compare annotated variants with the pathogenic mutation database to screen samples carrying pathogenic mutations; Risk assessment: Evaluate the pathogenicity of the mutations in the sample and their impact on potential carriers; S3, Data Visualization and Reporting Use R or Python to visualize data and display information such as mutation distribution and sample characteristics; Generate detailed test reports including mutation information, carrier risk assessment and clinical recommendations; S4. Results and Feedback Feedback analysis results to clinicians or researchers to discuss management of potential carriers and follow-up testing recommendations; Providing genetic counseling services to participants to help understand test results; S5. Quality Control and Update Update the database regularly to ensure the latest mutation information is captured; Strengthen quality control steps to ensure the accuracy and reliability of results; Through the above steps, an efficient and systematic data analysis platform was established to identify potential gene carriers.

5. The method for developing a product for screening carriers of a high incidence of single gene recessive genetic diseases during the peri-pregnancy period according to claim 1, characterized in that the specific process of the above step 4 is as follows: S1. Clinical trial design 1.1 Establishing research objectives Primary objectives: To validate the sensitivity, specificity, positive predictive value, and negative predictive value of the new method; Secondary objectives: To assess the applicability of the method in different populations; 1.2 Sample selection Inclusion criteria: Participants who meet specific population characteristics were selected; Exclusion criteria: Patients with other genetic diseases or syndromes were excluded to ensure the accuracy of the results; 1.3 Sample size calculation Use statistical methods to calculate sample size to ensure statistical significance and reliability of the trial results; S2. Implementation of the test 2.1 Recruiting participants Develop a clear recruitment plan to ensure that the necessary sample can be obtained; Recruitment was conducted through hospitals, community outreach, and genetic counseling centers to ensure representativeness of the sample; 2.2 Collecting samples Collect DNA samples from participants and ensure that the quality and storage conditions of the samples meet the standards; 2.3 Data Collection Define methods for data collection, including detailed medical and family histories and other relevant information; Design questionnaires or interviews to collect relevant information from participants for subsequent analysis; S3. Implement testing 3.1 Data Analysis Use the established data analysis platform to perform genome sequence analysis on the collected samples; Alignment, variant detection, and annotation were performed as described above; 3.2 Results Evaluation Statistically analyze test results and compare them with predefined standards; To assess differences in test results among different populations and the implications for early screening and intervention; S4. Data analysis and statistics 4.1 Statistical methods Use appropriate statistical tools for data analysis; Compare the sensitivity, specificity, positive predictive value, and negative predictive value of the results in different populations using relevant statistical methods such as the Chi-square test; 4.2 Interpretation of results Discuss the applicability of the method in different populations and compare it with existing literature; Identify factors that may influence the results; S5. Reporting and Release 5.1 Writing a research report Organize the research process, results and discussions, and write a complete clinical trial report; Emphasize the reliability of the method and its applicability to different populations; 5.2 Published Papers Publish research results in relevant academic journals to share experiences and findings; Participate in relevant academic conferences to present research results and obtain feedback; S6. Promotion of clinical application 6.1 Providing clinical advice Provide guidance to clinicians and genetic counselors based on the research findings; Develop specific clinical application guidelines to aid genetic disease screening and management; 6.2 Monitoring and Feedback Continuously monitor the effectiveness of the methods and collect feedback for continuous improvement; Regularly update testing procedures and analytical methods to ensure they adapt to new scientific advances; S7. Ethics and Compliance Ensure that clinical trials follow the guidance of the ethics committee and local laws and regulations, and obtain informed consent from patients; Regularly review the trial process to ensure that patient rights are protected.

Citation Information

Cited By

  • Pre-pregnancy carrier screening genetic counseling system based on large language model

    CN121034403A

  • A pre-pregnancy carrier screening genetic counseling system based on a large language model

    CN121034403B